Two patients with psoriasis and hepatitis B treated with secukinumab during COVID19 pandemic

Introduction
Secukinumab may be a safety option for patients with psoriasis and HBV infection because of its treatment mechanism.
Case report
Two patients with chronic hepatitis B who had used tenofovir disoproxil 245mg per day were suffering from psoriasis. For one, on July 31, 2019 treatment with standard dose secukinumab was started and for another on January 20, 2020. Although on March 11, 2020 COVID19 pandemic started in Turkey, we didn’t stop secukinumab treatments of our patients. Based on the start of treatment of secukinumab of our 50-year-old patient, after 8 weeks PASI 90 response and after 15 weeks PASI 100 response was reached and PASI 90 response was obtained in our 35-year-old patient after 5 weeks and PASI 100 response was reached after 18 weeks after starting secukinumab. Secukinumab treatments of our patients are going on.
Conclusion
Further long-term studies and case reports are needed to validate the safety and efficacy of secukinumab in patients with HBV. Our cases were deemed worthy of presentation because they were the first reported cases with psoriasis and HBV infection used secukinumab and tenofovir disoproxil in COVID19 pandemic.